

BARCELONA (Spain), June 18, 2024

## REIG JOFRE JOINS THE IBEX SMALL CAP INDEX

- The IBEX Technical Advisory Committee approved the inclusion of Reig Jofre (RJF) shares in the IBEX SMALL CAP during its latest ordinary review.
- This change will take effect from June 24, 2024. The index adjustment will be made at the close of trading on Friday, June 21.

**REIG JOFRE** (BME:RJF), a pharmaceutical company listed on the continuous market of the Spanish stock exchange, which researches, develops, manufactures, and markets essential pharmaceutical products for people's health, announces that the IBEX Technical Advisory Committee approved the inclusion of Reig Jofre (RJF) shares in the **IBEX SMALL CAP** during its latest ordinary review. This index is a national and international benchmark for the stock performance of small-cap Spanish companies.

This change will take effect from June 24, 2024, and the index adjustment will be made at the close of trading on Friday, June 21.

The IBEX indices, managed by *Bolsas y Mercados Españoles* (BME), are the main indicators of the Spanish stock market. These indices reflect the price evolution of securities listed on the Barcelona, Madrid, Bilbao, and Valencia stock exchanges.

BME compiles several financial indices, among which three main ones stand out, all weighted by free-float market capitalization: IBEX SMALL CAP, composed of the 30 most relevant small-cap companies that are not included in the IBEX Medium Cap or the IBEX 35. Additionally, companies must have a free-float capital greater than 15% and an annualized turnover on the free-float capital exceeding 15%.

**Laura Martí, CFO**, emphasized that *"The inclusion of Reig Jofre in the IBEX SMALL CAP strengthens our market position. This achievement will allow us to increase our visibility in the stock markets, deliver greater value to our current shareholders, and attract new investors."*

### About REIG JOFRE

REIG JOFRE is a pharmaceutical company born with the firm conviction of universalizing health, providing basic to innovative solutions to people worldwide. To deliver pioneering and high-impact solutions, they boast cutting-edge technological production and maintain continuous collaboration with other innovative companies, researchers, and startups, while constantly investing in R&D. Since 1929, they have been researching, developing, manufacturing, and marketing pharmaceutical products essential for people's health, under three major areas: Pharmaceutical Technologies, Specialty Pharmacare, and Consumer Healthcare. REIG JOFRE has four development and production centers in Europe, with its own teams in Spain, France, Portugal, Belgium, Sweden, the United Kingdom, and Poland, along with an extensive network of business partners in over 70 countries and over 1,300 employs. The company closed 2023 with a turnover of €316M (+17% vs. 2022) and an EBITDA of €35M (+15% vs. 2022) and is listed on the continuous market of the Spanish stock exchange under the ticker RJF.

---

### Further information

Inma Santa-Pau – Director of Communication and Public Relations - [isantapau@reigjofre.com](mailto:isantapau@reigjofre.com)

[www.reigjofre.com](http://www.reigjofre.com)